Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Capital Employed (2019 - 2025)

UroGen Pharma's Return on Capital Employed history spans 7 years, with the latest figure at 0.24% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 15.0% year-over-year to 0.24%; the TTM value through Dec 2025 reached 0.24%, up 15.0%, while the annual FY2025 figure was 0.18%, 34.0% up from the prior year.
  • Return on Capital Employed reached 0.24% in Q4 2025 per URGN's latest filing, up from 0.86% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.14% in Q3 2023 to a low of 1.23% in Q1 2021.
  • Average Return on Capital Employed over 5 years is 0.55%, with a median of 0.45% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: skyrocketed 65bps in 2022, then crashed -54bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.88% in 2021, then skyrocketed by 74bps to 0.23% in 2022, then crashed by -84bps to 0.42% in 2023, then increased by 8bps to 0.39% in 2024, then surged by 38bps to 0.24% in 2025.
  • Per Business Quant, the three most recent readings for URGN's Return on Capital Employed are 0.24% (Q4 2025), 0.86% (Q3 2025), and 0.68% (Q2 2025).